Acute Respiratory Distress
Conditions
Brief summary
1. To access role of vitamin C supplementation in ARDS patients on the following: Oxidants/ antioxidants imbalance Length of hospital stay Mortality rate Weaning from mechanical ventilator Incidence of adverse drug reaction 2. To access tolerability of vitamin C supplementation in patients with ARDS.
Detailed description
Acute Respiratory distress syndrome (ARDS) is a form of severe hypoxemic respiratory failure due to severe impairment of gas exchange and lung mechanics that is characterized by inflammatory injury to the alveolar capillary barrier, with extravasation of protein-rich edema fluid into the air space. Current ARDS antioxidant treatment strategy, is based upon supportive therapies including low tidal volume ventilation, fluid management, nutritional support and glucocorticoids. Ascorbic acid or Vitamin C is an important dietary water-soluble antioxidant, it significantly decreases the adverse effects of ROS such as reactive oxygen and nitrogen species that can cause oxidative damage to macromolecules. Recent studies show that high dose of Vitamin C have protective effects against overwhelming oxidative stress due to critical illness. Vitamin C improves immune function and improves tissue perfusion and reduce tissue hypoxia and subsequent organ dysfunction. Also, Ascorbate, the redox form of vitamin C is physiological antioxidant and has bacteriostatic activity Hence the study aims to evaluate the impact of IV Vitamin C in ARDS, as a novel pharmaceutical approach in an attempt to improve the clinical outcome of ARDS patients, decrease other medications toxicities and improve patients' quality of life. The objective of the current study was to evaluate the efficacy, safety and tolerability of IV Vitamin C administration in addition to conventional therapy in patients with ARDS by assessing the following: 1. Oxidants/ antioxidants imbalance 2. Length of hospital stay 3. Mortality rate 4. Weaning from mechanical ventilator 5. Incidence of adverse drug reaction 6. Serum IL8 levels 8\. Serum Vitamin C levels
Interventions
DIETARY_SUPPLEMENTvitamin c
vitamin c IV 10 G
Sponsors
Misr International University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. All ARDS cases presenting to the Chest department ICU within 48 hours of diagnosis 2. who don't have an
Exclusion criteria
will be included.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Improvement in ARDS patient's mortality rate | within 10 days of ARDS diagnosis | Days to weaning from ventilator |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Intensive Care Unit Length of Stay | subject will be followed until discharged from the ICU, has deceased, or study duration has reached 10days from time of enrollment, whichever is first | improvement in clinical outcome |
| Duration of Mechanical Ventilation | subject will be followed until mechanical ventilation has been discontinued, the subject has deceased, or study duration has reached 10 days from time of enrollment, whichever is first | improvement in respiratory functions |
Countries
Egypt
Outcome results
None listed